ArticleInternal medicine (Tokyo, Japan)2026
Early Recovery from Cryptogenic NORSE Following Repeated C-NORSE Score Assessment and Cyclophosphamide Treatment.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus.Epilepsia · 2026Article
- Blockade of Interleukin-6 Receptor with Tocilizumab During the Acute Phase of Childhood Immune-Mediated Epilepsy can Lead to a Favorable Outcome - an Observational Study.Current neuropharmacology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptogenic new-onset refractory status epilepticus (C-NORSE) is a rare, severe condition characterized by refractory status epilepticus without identifiable causes. It is often unresponsive to first-line immunotherapy. The C-NORSE score is a useful diagnostic tool, but in the early phase, when the score remains low and antibody test results are unavailable, it is difficult to initiate second-line immunotherapy, including cyclophosphamide. We report a 27-year-old man with C-NORSE who achieved early recovery and favorable outcome following administration of intravenous cyclophosphamide, despite a low C-NORSE score on admission, suggesting the importance of repeated assessment using the C-NORSE score and early administration of cyclophosphamide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.